ID   12370
AC   CVCL_JY27
DR   cancercelllines; CVCL_JY27
DR   Wikidata; Q54581195
RX   PubMed=25862976;
RX   PubMed=31150822;
CC   Doubling time: 6-9 days (PubMed=25862976).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.His193Pro (c.578A>C); ClinVar=VCV000376612; Zygosity=Unspecified (PubMed=25862976; PubMed=31150822).
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: Age at sampling from personal communication of Castillo-Tong, Dan Cacsire.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=31150822
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D12S391: 17
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 14,17
ST   D19S433: 14,15
ST   D1S1656: 17.3
ST   D21S11: 28,29
ST   D2S1338: 19,23
ST   D3S1358: 14,17
ST   D5S818: 10,11
ST   D6S1043: 13
ST   D7S820: 7,8
ST   D8S1179: 12,13
ST   FGA: 20
ST   Penta D: 11,13
ST   Penta E: 7,9
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 19-12-24; Version: 11
//
RX   PubMed=25862976; DOI=10.1016/j.canlet.2015.03.040;
RA   Kreuzinger C., Gamperl M., Wolf A., Heinze G., Geroldinger A.,
RA   Lambrechts D., Boeckx B., Smeets D., Horvat R., Aust S., Hamilton G.,
RA   Zeillinger R., Castillo-Tong D.C.;
RT   "Molecular characterization of 7 new established cell lines from high
RT   grade serous ovarian cancer.";
RL   Cancer Lett. 362:218-228(2015).
//
RX   PubMed=31150822; DOI=10.1016/j.canlet.2019.05.032;
RA   Kreuzinger C., von der Decken I., Wolf A., Gamperl M., Koller J.,
RA   Karacs J., Pfaffinger S., Bartl T., Reinthaller A., Grimm C.,
RA   Singer C.F., Braicu E.I., Cunnea P., Gourley C., Smeets D., Boeckx B.,
RA   Lambrechts D., Perco P., Horvat R., Berns E.M.J.J., Castillo-Tong D.C.;
RT   "Patient-derived cell line models revealed therapeutic targets and
RT   molecular mechanisms underlying disease progression of high grade
RT   serous ovarian cancer.";
RL   Cancer Lett. 459:1-12(2019).
//